APRICUS

CompletedPhase 2

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity

Lead sponsor

AstraZeneca

Asset

AZD6234

Subcutaneous · Amylin analog

Listed sites

Recruiting sites

Actual enrollment

262

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥30

Primary endpoints

•Body weight•Weight loss ≥ 5% from baseline weight

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06595238

Org study IDD8750C00004

Secondary ID2024-514000-13-00EU CT number

Timeline

Milestones

Study first posted2024-09-19actual

Study start2024-10-01actual

Primary completion2025-08-08actual

Study completion2025-12-03actual

Last update posted2025-12-17actual

Assets

Investigational agents

AZD6234

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Adults ≥ 18 years of age

•BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated)

•A stable body weight for 3 months prior to Screening (±5% body weight change)

Exclusion criteria

•Have obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome

•Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening

•Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)

•History of type 1 diabetes mellitus or T2DM

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Safety / tolerability / PK

Weight & body composition

6 endpoints

Primary/protocol endpoint

Percent change in body weight from baseline to week 26

Time frame:26 weeks

percent change from baseline, improvement

Primary/protocol endpoint

Weight loss ≥ 5% from baseline weight to week 26

Time frame:26 weeks

threshold achievement, improvement

Secondary/protocol endpoint

Weight loss ≥ 5% from baseline to week 36

Time frame:36 weeks

threshold achievement, improvement

Secondary/protocol endpoint

Weight loss ≥ 10% from baseline to week 36

Time frame:36 weeks

threshold achievement, improvement

Secondary/protocol endpoint

Percent change in body weight from baseline to week 36

Time frame:36 weeks

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute change in body weight (kg) from baseline to week 26 and week 36

Time frame:week 26 and week 36

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

AZD6234 plasma concentrations

Time frame:Week 43

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.